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Summary.-The effects of C. parvum on RFM/UN myeloid leukaemia were studied.
Mice inoculated with 7-0 mg but not0-7 mg C.parvum i.p. survived significantly longer
than untreated leukaemic mice (P < 0-001). Administration of silica abrogated
the effects of C. parvum, whilst polyvinyl pyridine-N-oxide prevented the inhibitory
effects of silica. These studies demonstrate that a single large dose of C. parvum,
either before or after leukaemic-cell passage, can significantly prolong the survival
of RFM mice bearing myeloid leukaemia. The effects of silica and PVNO on C.
parv'um suggest a critical role for macrophages in C. parvum effects on myeloid
leukaemia.
C. Parrvrn is a non-specific stimulator
of the immune system which has been
shown to exert antitumour activity i
both animal (Currie & Bagshawe, 1970;
Scott, 1974a; Fisher et al., 1975; Suit et
al., 1977; Houchens et al., 1976) and
human tumours (Scott, 1974b; Israel et
al., 1975; Fisher et al., 1976).
In this communication we report our
initial studies of the effects of C. parrurn
on murine myeloid leukaemia (Preisler et
al., 1977). The effects of this immune
stimulator are dose-dependent and demon-
strable by the prolongation of survival of
leukaemic mice. The administration of
silica prevents the beneficial effects of
C. parvum on this leukaemia, whilst
polyvinyl pyridine N-oxide (PVNO) abro-
gates the inhibitory effects of silica.
AIATERIALS AND METHODS
A. Mice and tumour. Inbred RFM/UN
female mice were used in these experiments.
The mice were bred in our own animal facility.
The pathophysiology of this murine leukae-
mia has been previously described (Preisler
et al., 1977). Mice, were inoculated i.v. with
spleen-cell suspensions from terminal leukae-
mic RFM mice, with the appropriate number
of cells suspended in 0-2 ml saline. There
were 5 mice in each experimental group,
and food and water were allowed ad lib. At
death, internal organs wvere inspected and
livers and spleens weighed and fixed in
formalin for hiistopathological studies. Each
experiment was performed at least 3 times.
B. C. parrum -The C. parrurn which
wAas kindly furnished by Burroughs 'ellcome
Company Research, Triangle Park, N.C.,
U.S.A., contained 7 mg dry weight of
formalin-killed organisms per millilitre, sus-
pended in 0-9o NaCl solution. Within each
experiment varying, amounts of C. parvum
were always injected by the same route and
in the same total volume.
C. Silica, polyvinyl pyridine N-oxide
(PVNO).-In some experiments mice re-
ceived either silica (2-5 mg in 1 ml PBS)
i.v. on the day of tumour transplantation
(i.e. 2 days before inoculation of C. parvum
where applicable) and/or P VNO (4 mg in
01 ml PBS) s.c. one day before tumour
transplantation.
RESULTS
EJffects of administration of C. parvurn
before or after passage of disease
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doses of C. parvctnt 2 days before or
after inoculation with 104 leukaemic
spleen cells. No increase in life span was
detected with the lowest doses of C.
parvum (0.07 or 0 35 mg). With increasing
doses there was a corresponding increase
in life-span, with the 7 mg dose providing
the greatest increase (Table I). At this
TABLE I. Effects of differing doses of C.
parvum on the survival of lettkaemic
mice
C. porvum
Dose (mg) Day Do
tJntreate(1 controls 16
7 0 -2 19
3 .5 2 19
0 7 2 18
0 :35 2 18
0 07 2 16 5
0 07 ±2 17
3- 5 -2 20
0 7 2 18
0 35 +2 16
7 0 +2 24
*Increase in life span.
Median survival time
iys Range %ILS*
(17-20)
(17-21)
(17-18)
(17-18)
(16-18)
(16-18
(18-20)
(17-21)
(16-18)
(19-26
19
19
12 *5
12 -5
3
6
25
125
0
50
dose level, C. parvunn was effective in
prolonging survival whether administered
before or after the passage of the leu-
kaemia.
Effects of C. parvum on established disease
Mice were inoculated with either of
2 doses of C. parvum 2 days after receiving
104 leukemic cells. Consistent with the
previous experiment (Table I), the aver-
age life span of mice treated with 0 7 mg
of C. parvum was only slightly increased,
whilst the survival of mice given 7 mg
was significantly prolonged (Table III).
A life-table graph combining the results
of these experiments is shown in Fig. 1.
While the difference between the sur-
vival of mice inoculated with 0 7 mg of
C. parvu,m and the control mice was not
statistically significant (P > 0.05), the
difference in survival between mice receiv-
ing 7 mg of C. parvuum and the control
0
w_ 40.
20.1
CONTROLS I,
II CP.7
% P
I
\\ I
\-.
5. 10. 15. 20. 2S. 30. 35. '0.
SURVIVAL IN CAYS
FIG. 1. Cumulative survival for mice in
Experiments 1-5 (Table III).
mice was highly significant (P < 0 001,
Breslow test).
Histopatholoqical studies
At the time of death, control leukaemic
mice and those inoculated with C. parvum
had massive hepatosplenomegaly, with
diffuse infiltration by leukaemic cells.
Leukaemic-cell thrombi of the pulmonary
arteries appeared to be the immediate
cause of death of both treated and
control mice (Fig. 2). Mice which had
been inoculated with C. parruvn differed
from control mice in that organ infiltra-
tion by leukaemic cells was less. There
was evidence of significant tissue necrosis
only in the spleens and livers of mice
which had been inoculated with C. par-
vum. The histopathological findings in
the mice receiving 0 7 and 7 0 mg C.
parvum were indistinguishable at the
time of death (Fig. 3).
Effects of silica and PIYNO on leukacinic
mice inoculated with C. parvurun
In 3 of the experiments described in
Table II, groups of mice received silica
and/or PVNO in addition to or instead
of C. parvum. Table III gives the median
survival times and ranges for these mice.
On an a posteriori contrast test, the
least-significant-difference test was used
7()4
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FIG. 3. Liver and spleen from a mouse
treated with 0 7 mg C. parvum 2 days
after inoculation with 104 leukaemic spleen
cells i.v. (a) Extensive necrosis of liver
tissue and sparse infiltration by leukaemic
cells. (b) Numerous necrotic cells, normal
spleen cells and rare leukaemic cells.
Fia. 2. Liver, spleen and lung from an
untreated control RF mouse (dying from
myeloid lutekaemia. Haematoxylin an(d
eosin. (a) Massive leukaemic infiltration of
the liver. (b) Replacement of inormal
splenic architecture by leukaemic cells.
(c) A ptulmonary capillary thrombus
cornpose(l of leukaemic cells, eiythrocytes,
fibrin, an(d necrotic cells.
to determine which experimental groups
were significanitly differentfrom each other.
The administration of silica, PVNO, or
PVNO + silica had no effect on the
survival of mice, compared to the control
group. By contrast, survival was signifi-
cantly prolonged in mice which received
C. parvum or PVNO + C. parvum. The
administration of silica to mice which
received C. parvum abrogated the
increase in survival produced by C.
parvrum. The administration of PVNO to
mice which received silica and C. parvum
abrogated the inhibitory effects of silica
and restored the beneficial effects of C.
parvum. The observation that mice which
received C. parvum together with PVNO
survived the longest is of interest.
(a)
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(b3
(c)
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TABLE II. Effects of 2 doses of C. parvum (CP) on the survival of leukaernic mice
2
0,
ILS
5
6 5
24 5
5
14 5
4(6 5
MIST Raiige
13
13
2:3
I16
18
21
12-14
12-14
16-23
5_*1
165*2
J5 *1
0
ILS
0
77
# AIST Range
5 15 14-16
5 12 11--13
5 18 14-25
Total (5 expts)
25
19 30
31 :30
15 11 19*1
16 11-20*2
20 5 14--25*4
ILS
24)
7
:37
Mice were inoculated with 104 leukaemic cells. Two (lays later they received 0 7 mg or 7 0 mg C. parruio
i.p.
* Asterisk with a number indicates ssurvivors at Day 90.
# Number of mice.
MST Median survival time ((lays).
ILS Increase in life spain.
TABLE III.- -Effect of silica and PVNO on anti leukaemnia efficacy of C. parvum
I II III
1.Conitrol
2. CP
3. Si
4. Si+CP
5. P
6. P+Si
7. P+CP
8. P+Si+CP
MST Range
17 11-19
21 14-23
16
15
16
17
24
22
10-
15-
15-
15-
21-
-20
-17
-19
-32
-24
AIST
15
18
1:3
16
12
14
20
17
Range
14-16
14-25
11.13
14-17
12-13
13-15
16-73*
16-18
MST
15
21
18
13
17
32
19
26
Range
14-16
16-25
16-18*
11-21
17-19
18-32t
13-28
20-26t
*One mouse survive(l > 90 (lays.
tTwo mice survived > 90 days.
Mice received the various treatments as (lescribe(l in the
Methods section. Statistical analysis demonstrated that mice
in Groups 2 and 8 live(d significantly longer than mice in GIouPps
1, 3, 4, 5, 6 (P < 0 05) and mice in Group 7 lived longei than
mice in Grouips 2 anldl 8 (P < 0.05).
DISCUSSION
The studies demonstrate that the ad-
ministration of a single large dose of C.
parvum can significantly prolong survival
in RFM mice bearing myeloid leukaemia.
C. parvrum given 2 days before trans-
plantation of the leukaemia produced a
slight ( > 200,/) prolongation of survival.
When administered 2 days after the
passage of the leukaemia, no significant
effect was seen with 0 7 mg C. parvum,
but 7 0 mg consistently produced an
increase in life span. Dose-dependent
therapeutic effects of C. parvuan have
been described in P388 leukaemia
(Houchens et al., 1976), which is the only
murine leukaemia in which C. parvum
alone has been found to be effective
(Houchens et al., 1976; Mathe et al., 1969;
Scott, 1974a). The dose levels of C. parvum
in the previously reported studies were
much lower than the 250-300 mg/kg levels
in our studies. This difference in dose
levels may in part explain the apparent
lack of effectiveness of C. parvum in the
tested systems. Also, L1210 and AKR
leukaemias are lymphoid malignancies,
passaged i.p. in the reported experi-
ments, which may for these reasons have
responded differently to C. parvrum from
our myeloid leukaemia.
C. parvum has been shown to be a
general stimulant of the reticuloendo-
thelial system and of macrophages
(Woodruff and Dunbar 1973). Silica has
been shown to decrease macrophage func-
Expt
MST
21
18
21
Control
CP 0 7 mg
CP 7 mg
Expt
Control
CP 0 7 mg
CP 7 mg
Range
11-19
16 20
14-23
4
5
5
5
5
10
10
14 12-14
16 15-19
20 5 16-*3
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tion because of its effects upon lysosomal
membranes. Silica-induced inhibition of
macrophage function can be prevented
by the prior administration of the macro-
phage stabilizer PVNO, an observation
similar to that reported by Lotzova &
Cudkowicz (1974) with respect to marrow
grafts. These observations, taken together
with those now reported, lead to the
conclusion that the increased survival of
mice with myeloid leukaemia is dependent
upon stimulation of intact macrophage
function. This has been shown in several
other tumour systems (McBride et al.,
1975; Keller, 1977; Jones & Castro, 1977).
One cannot conclude, however, that
phagocytic macrophages are the immedi-
ate effectors of antitumour resistance,
since the activity of natural killer cells
has also been shown to be augmented by
C. parvum and inhibited by silica (Oehler
& Herberman 1978a). Because natural
killer cells are not phagocytic, it has been
suggested that the effects of C. parvum
and silica on these cells are indirect, and
mediated by the effects ofthese agents on
the reticuloendothelial system (Oehler et
al., 1978b).
Histopathologic studies of leukaemic
mice treated with C. parvum showed
hepatosplenomegaly, with necrotic areas
in the liver and spleen, as previously
described by Lampert et al. (1977),
possibly caused by intravascular coagu-
lation resulting from antigen-antibody
interaction. In preliminary studies we
found that the administration of C.
parvum to normal mice did not cause
death. The terminal event in the leukae-
mic mice appeared to be leukaemic-cell
pulmonary emboli and/or thrombi, the
apparent immediate cause of death of
mice with this myeloid leukaemia (Preisler
et al., 1977). Hence, despite toxicity
related to the administration ofC.parvum,
the mice ultimately died from leukaemia.
The studies described here suggest that
the administration of C. parvum might be
of therapeutic benefit for patients with
acute myelocytic leukaemia. An initial
study of C. parvum in the treatment of
leukaemia in man failed to demonstrate
any therapeutic benefit (Pavlovsky et al.,
1978). On the basis of our dose-response
experience in the mouse studies presented
here, one would expect to see therapeutic
benefit only with C. parvum doses which
are far in excess of any doses hitherto
administered to man. Clearly the hepato-
splenic toxicity seen at the high doses
administered to our mice would seem to
make such an attempt unwise. Because of
the possible relationship between the
presence of C. parvum bacilli in the
bloodstream and the toxic manifesta-
tions, we are currently attempting to
circumvent this problem by encapsulating
the bacilli within phospholipid vesicles
(Papahadjopoulos and Preisler, unpub-
lished observation). Since i.v. adminis-
tered phospholipid vesicles are rapidly
cleared by the reticuloendothelial system,
we will attempt to deliver the encapsu-
lated C. parvum directly to the phagocytic
cells of reticuloendothelial system while
avoiding direct exposure of other tissues
to the bacterium.
This study has been supported by USPHS Grant
No. CA-17785.
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